Kailera Therapeutics
KLRA
11.02
-0.56
-4.84%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
11.02
-0.56
-4.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Kailera Therapeutics
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.
- Founded
- 2024
- CEO
- Mr. Ronald C. Renaud, Jr,M.B.A.
- Employees
- 145
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- kailera.com
Company profile
- Exchange
- US
- Symbol
- KLRA
- Market-cap rank
- #3073
- Listing date
- 2026-04-17
- Market cap
- 1.43B
- Float cap
- 644.43M
- Shares out
- 129.85M
- Float shares
- 58.48M
Sectors & themes
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Kailera Therapeutics discussion 0 comments